Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III (MONALEESA-3) Trial for the Treatment of HR+/HER2- Advanced Breast Cancer
- The P-III (MONALEESA-3) trial evaluates Kisqali + fulvestrant vs fulvestrant alone in postmenopausal women with HR+/HER2- advanced or metastatic breast cancer
- The updated analysis showed a significant OS benefit of nearly 16mos., 33% relative reduction in risk of death, m-OS (67.6mos. vs 51.8mos.) with a median follow-up of 5yrs., patients experienced an additional 1yr. delay to subsequent CT (49.2mos. vs 29.0mos.)
- Additionally, survival rate (56.5% vs 42.1%) @5yrs., (16.5% vs 8.6%) of patients were still ongoing on therapy with no new AES, 28% reduction in the risk of death in an exploratory analysis at a median of 71mos. The results will be presented at ESMO 2022
Ref: Novartis | Image: Novartis
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].